Source link : https://www.newshealth.biz/health-news/novel-agent-reduces-monthly-migraine-days/
Investigational Lu AG09222 bested placebo in preventing migraine in a phase II trial. The treatment showed a 2-day difference in reducing monthly migraine days. Lu AG09222 targets PACAP, a vasodilating polypeptide. A monoclonal antibody targeting a novel migraine prevention pathway showed success in the phase II HOPE trial. A single 750 mg intravenous infusion of […]
Author : News Health
Publish date : 2024-09-04 21:30:24
Copyright for syndicated content belongs to the linked Source.
